Ho Soo Chun1,2, Jae Seung Lee1,2,3, Hye Won Lee1,2,3, Beom Kyung Kim1,2,3, Jun Yong Park1,2,3, Do Young Kim1,2,3, Sang Hoon Ahn1,2,3, Seung Up Kim4,5,6. 1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. 2. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea. 4. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. ksukorea@yuhs.ac. 5. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea. ksukorea@yuhs.ac. 6. Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea. ksukorea@yuhs.ac.
Abstract
BACKGROUND: The association between chronic hepatitis B (CHB) and cardiovascular disease (CVD) remains unclear. We investigated the prevalence and risk factors of CVD in patients with CHB. METHODS: Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analyzed. Significant liver fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile, highest Forns index quintile, or fibrosis-4 ≥ 2.67. The CVD risk was calculated using the 10-year atherosclerotic cardiovascular disease (ASCVD) risk score from the 2013 ACC/AHA Guidelines. RESULTS: Among the 506 subjects with CHB, 15 (3.0%) and 150 (29.6%) patients had a CVD history and significant liver fibrosis, respectively. Patients with CVD history were significantly older; showed a significantly higher prevalence of hypertension, metabolic syndrome, and significant liver fibrosis; and had a significantly higher platelet count, lower aspartate and alanine aminotransferase levels, higher triglyceride level, lower high-density lipoprotein level, and higher ASCVD risk than those without (all p < 0.05). In multivariate analysis, higher ASCVD risk (odds ratio [OR] = 1.090) and significant liver fibrosis (OR = 4.341) independently predicted the risk of CVD history (p < 0.05). The prevalence of CVD risk (6.7% vs. 1.4%; OR = 5.014) and high ASCVD risk (> 15%) (34.0% vs. 7.3%; OR = 6.538) was significantly higher in patients with significant liver fibrosis than in those without (all p < 0.05). CONCLUSIONS: Significant liver fibrosis was independently associated with the risk of CVD history in patients with CHB. Prospective studies are needed to validate the longitudinal association between fibrotic burden and CVD development in patients with CHB.
BACKGROUND: The association between chronic hepatitis B (CHB) and cardiovascular disease (CVD) remains unclear. We investigated the prevalence and risk factors of CVD in patients with CHB. METHODS: Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analyzed. Significant liver fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile, highest Forns index quintile, or fibrosis-4 ≥ 2.67. The CVD risk was calculated using the 10-year atherosclerotic cardiovascular disease (ASCVD) risk score from the 2013 ACC/AHA Guidelines. RESULTS: Among the 506 subjects with CHB, 15 (3.0%) and 150 (29.6%) patients had a CVD history and significant liver fibrosis, respectively. Patients with CVD history were significantly older; showed a significantly higher prevalence of hypertension, metabolic syndrome, and significant liver fibrosis; and had a significantly higher platelet count, lower aspartate and alanine aminotransferase levels, higher triglyceride level, lower high-density lipoprotein level, and higher ASCVD risk than those without (all p < 0.05). In multivariate analysis, higher ASCVD risk (odds ratio [OR] = 1.090) and significant liver fibrosis (OR = 4.341) independently predicted the risk of CVD history (p < 0.05). The prevalence of CVD risk (6.7% vs. 1.4%; OR = 5.014) and high ASCVD risk (> 15%) (34.0% vs. 7.3%; OR = 6.538) was significantly higher in patients with significant liver fibrosis than in those without (all p < 0.05). CONCLUSIONS: Significant liver fibrosis was independently associated with the risk of CVD history in patients with CHB. Prospective studies are needed to validate the longitudinal association between fibrotic burden and CVD development in patients with CHB.
Authors: Shanthi Mendis; Dele Abegunde; Salim Yusuf; Shah Ebrahim; Gerry Shaper; Hassen Ghannem; Bakuti Shengelia Journal: Bull World Health Organ Date: 2005-11-10 Impact factor: 9.408
Authors: Byung Seok Kim; Yeon Seok Seo; Young Seok Kim; Chang Hyeong Lee; Han Ah Lee; Soon Ho Um; Jeong-Ju Yoo; Sang Gyune Kim; Sang Jun Suh; Young Kul Jung; Sang Hoon Ahn; Kwang-Hyub Han; Hyung Joon Yim; Seung Up Kim Journal: J Gastroenterol Hepatol Date: 2018-02 Impact factor: 4.029
Authors: S Kiechl; G Egger; M Mayr; C J Wiedermann; E Bonora; F Oberhollenzer; M Muggeo; Q Xu; G Wick; W Poewe; J Willeit Journal: Circulation Date: 2001-02-27 Impact factor: 29.690
Authors: Seung Up Kim; Yeon Seok Seo; Han Ah Lee; Mi Na Kim; Yu Rim Lee; Hye Won Lee; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seong Gyu Hwang; Kyu Sung Rim; Soon Ho Um; Won Young Tak; Young Oh Kweon; Beom Kyung Kim; Soo Young Park Journal: J Hepatol Date: 2019-04-06 Impact factor: 25.083